Fertility Preservation — Cost, Top Hospitals & Success Rates | MyMedicPlus

Fertility preservation encompasses medical, surgical, and laboratory interventions designed to protect future reproductive potential for individuals facing circumstances that may compromise fertility. The primary indication driving modern fertility preservation medicine is oncology — cancer treatments including chemotherapy (particularly alkylating agents: cyclophosphamide, busulfan), pelvic radiotherapy, and gonadotoxic procedures carry substantial risk of premature ovarian insufficiency in women and azoospermia in men. The American Society for Clinical Oncology (ASCO) and ESHRE now mandate that fertility preservation counselling be offered to all reproductive-age cancer patients before initiating treatment.

Elective fertility preservation for social or professional reasons — colloquially 'social egg freezing' — has grown substantially since vitrification (ultra-rapid cryopreservation) made oocyte survival rates comparable to embryo cryopreservation. Women delaying childbearing for personal reasons can bank eggs during their peak reproductive years (typically 20s–early 30s) for future use, though absolute success rates remain age-dependent and informed consent must include realistic counselling about outcomes. Trans and gender-diverse individuals increasingly access fertility preservation before gender-affirming hormone therapy or surgery, as these treatments may impair future fertility. Patients experiencing symptoms should seek timely evaluation by a board-certified specialist for accurate diagnosis, staging, and personalised treatment planning using current clinical guidelines.

Cancer patients are the primary fertility preservation population: female patients facing chemotherapy, radiotherapy, or surgical procedures (oophorectomy) for haematological malignancies (leukaemia, lymphoma), solid tumours (breast, ovarian, cervical, colorectal cancer), and paediatric cancers. Ovarian transposition (oophoropexy) moves the ovaries out of the radiotherapy field before pelvic radiation. Gonadotrophin-releasing hormone agonist (GnRHa) co-treatment during chemotherapy may provide partial ovarian protection by suppressing gonadotrophin levels, though evidence for this approach is moderate.

Non-oncology indications include: premature ovarian insufficiency (familial POI or autoimmune), BRCA1/2 carriers planning risk-reducing salpingo-oophorectomy, women with severe endometriosis undergoing repeated ovarian surgery (each surgery reduces ovarian reserve), and women with conditions requiring bone marrow transplantation (alkylating agent conditioning). Male patients facing chemotherapy or radiation, spinal cord injury patients, and men with severe progressive oligospermia banking sperm before further deterioration are important fertility preservation populations.

For oncology patients, fertility preservation is recommended before any gonadotoxic treatment — the window is often 2–4 weeks, as most chemotherapy regimens can be safely delayed by this period with oncological safety for solid tumours (urgent haematological malignancies may not allow delay). Pubertal females (who have begun menstruating) can undergo ovarian stimulation and egg or embryo freezing; pre-pubertal children may have ovarian tissue cryopreservation as an experimental option. Ovarian reserve should be assessed before stimulation — even patients with borderline reserve benefit from banking whatever eggs are available.

For elective (social) egg freezing, women with AMH below 1.0 ng/mL or AFC below 5 have low expected yields and should be counselled about realistic expectations (low egg numbers per cycle requiring multiple cycles). Optimal age for social freezing is 32–36 — earlier banking yields more eggs but may result in long-term storage if pregnancy is not attempted for decades; later banking yields fewer eggs. Male sperm banking has no meaningful age or health contraindications and can be completed in a single visit — all men facing gonadotoxic treatment should be offered this before therapy.

Oocyte cryopreservation (egg freezing): the standard fertility preservation option for adult females. Controlled ovarian stimulation with FSH injections over 10–14 days harvests multiple mature oocytes, which are cryopreserved by vitrification (survival rate greater than 90%). For cancer patients, a random-start protocol can initiate stimulation at any cycle day, reducing delay to 2–3 weeks. Letrozole co-stimulation minimises oestrogen elevation for oestrogen-sensitive cancers (breast cancer).

Embryo cryopreservation: established (highest success rates) — requires partner or donor sperm at time of egg retrieval; ideal for couples or single women with a sperm source. Vitrified embryo survival exceeds 95%, with live birth rates per FET of 35–55% for blastocysts banked at younger ages.

Ovarian tissue cryopreservation: surgical removal and cryopreservation of cortical ovarian tissue, later reimplanted near or on the ovary after cancer treatment — restores hormonal function and natural fertility in 30–40% of cases. Now considered established for pre-pubertal cancer patients where stimulation is not feasible, and used in adults when treatment is too urgent for stimulation. Risk of reimplanting malignant cells exists for certain haematological cancers.

Sperm cryopreservation: simplest, most established male fertility preservation — masturbation sample collected, processed, cryopreserved indefinitely. Testicular sperm extraction (TESE) is used for azoospermic men before treatment.

Oocyte vitrification survival rates now exceed 90%, with fertilisation rates per thawed egg of 70–80% and live birth rates per transfer using vitrified eggs similar to fresh eggs in experienced centres (35–55% for eggs frozen under age 35). The estimated probability of live birth per frozen egg cycle is approximately 5–7% per egg banked, meaning 10–15 eggs provides approximately 50–70% cumulative chance of one live birth. These statistics are age-dependent and improve substantially with younger banking age.

For post-oncology patients, return of spontaneous fertility occurs in 30–50% — fertility preservation provides an additional option when natural return of fertility does not occur. Ovarian tissue reimplantation has achieved over 200 live births worldwide, with function lasting 3–7 years after reimplantation. Psychologically, the option of fertility preservation significantly reduces cancer-related fertility anxiety in young patients, improving quality of life during and after treatment — even for patients who ultimately never use their frozen reproductive material.

Ovarian stimulation risks include OHSS (1–2% severe) and procedure-related egg retrieval complications (bleeding, infection, anaesthetic risk) at very low rates. Stimulation delay for cancer patients is typically safe (2–4 weeks) for most solid tumours but requires oncological team sign-off — urgent haematological malignancies may not allow delay. Oestrogen elevation during stimulation is a concern for oestrogen-receptor-positive breast cancers; tamoxifen or letrozole co-stimulation protocols minimise this risk.

For ovarian tissue cryopreservation, the surgical risk of laparoscopic oophorectomy is low. Reimplantation carries a theoretical risk of reintroducing malignant cells — particularly for haematological cancers — and this must be discussed with the oncology team. No guarantees of future success are possible — egg quality may be compromised by age or the underlying cancer treatment, and a meaningful proportion of stored eggs will not lead to a live birth. The financial and emotional investment of fertility preservation without guaranteed returns should be clearly communicated.

After egg retrieval, patients recover over 24–48 hours with mild pelvic discomfort and bloating. Activities resume within 3–5 days for most. Cancer treatment can begin within 5–7 days after egg retrieval in most cases. Stored reproductive material (eggs, embryos, sperm, ovarian tissue) remains viable indefinitely when cryopreserved properly — legal storage limits vary by country (10 years with extensions in UK; indefinite in most other jurisdictions).

Fertility preservation patients require annual contact with the storage facility to maintain storage status and update future intentions. When ready to use banked eggs or embryos, a standard FET preparation protocol is followed. For ovarian tissue, reimplantation timing is planned with the oncology team once cancer remission is confirmed and further gonadotoxic therapy is not anticipated. Male patients with banked sperm use it for ICSI when required. Fertility counselling and psychological support should accompany all follow-up visits.

Egg freezing costs in the United States range from USD 6,000–15,000 per stimulation cycle (including monitoring and retrieval), with annual storage fees of USD 400–1,000. Medications add USD 3,000–6,000 per cycle. Multiple cycles are often needed to bank sufficient eggs. Embryo freezing costs are similar; ICSI adds USD 1,000–2,500.

Medical tourism for fertility preservation: India offers complete egg freezing cycles including medications and storage for USD 1,500–3,000; embryo freezing USD 2,000–4,000. Thailand: egg freezing USD 3,000–5,000 per cycle. Spain: EUR 3,500–6,000 per cycle at leading centres. For cancer patients, many oncology centres in Europe offer subsidised or reduced-cost fertility preservation; in the US, the LIVESTRONG Fertility programme provides grants for qualifying oncology patients. Sperm banking costs USD 500–1,500 for collection and first year storage (essentially universally affordable).

For women choosing not to undergo fertility preservation, assisted reproduction with donor eggs after treatment-induced ovarian failure provides live birth rates of 55–65% per FET irrespective of recipient age, with no need for prior stimulation. GnRH agonist co-treatment during chemotherapy (Zoladex/Lupron) provides partial ovarian protection by temporarily suppressing ovarian activity — not a replacement for established fertility preservation methods but may reduce the degree of ovarian damage in hormone-sensitive cancer types.

For women with diminished ovarian reserve who need more eggs than one stimulation cycle can provide, sequential stimulation (in vitro maturation — IVM — of immature eggs, dual stimulation protocols, or random-start protocols stacked before oncological treatment) maximises egg yield in a compressed timeframe. Surrogacy with banked embryos is an alternative for women who cannot carry pregnancy after cancer treatment (uterine or significant radiation damage). Male partners of cancer patients can bank sperm as a straightforward low-cost parallel fertility protection step.